Anti-CD19 (FMC63) CAR Immunogenicity ELISA Kit
背景（Background）
FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.Anti-fmc63 scFv antibody can specifically bind to the antigen recognition epitope of fmc63 scFv on anti-CD19 car, and it shows high specificity and sensitivity,it's used to detect the expression of fmc63 scFv derived car.
原理（Assay Principles）
This assay kit employs a bridging-ELISA format, providing a rapid detection of FMC63 ADA. The kit consists High-bind Plate and Mouse FMC63 scFv and FMC63 ADA Standard and Biotin-Mouse FMC63 scFv and Streptavidin-HRP and buffers.
Your experiment will include 4 simple steps:
a) Coat the plate with Mouse FMC63 scFv.
b) Add your molecule of interest to the tests.
c) Add Mouse FMC63 scFv-Biotin.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
應(yīng)用說(shuō)明（Application）
This kit is developed for detection of Anti-CD19 (FMC63) antibodies in CAR Immunogenicity assay test. Detection and monitoring the level of ADA is important to fully understand the potential immune responses.
It is for research use only.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
存儲(chǔ) & 運(yùn)輸（Storage & Shipping）
The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
The kit shipped at room temperature that had been validated. Please contact us if you need blue ice shipping, but additional freight may be followed.
Below is the Shipping Statement for Kit Products.
關(guān)鍵字： FMC63 ELISA Kit;FMC63試劑盒;FMC63 ELISA試劑盒;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國(guó)生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶(hù)超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。